CO7151489A2 - Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo - Google Patents

Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo

Info

Publication number
CO7151489A2
CO7151489A2 CO14270817A CO14270817A CO7151489A2 CO 7151489 A2 CO7151489 A2 CO 7151489A2 CO 14270817 A CO14270817 A CO 14270817A CO 14270817 A CO14270817 A CO 14270817A CO 7151489 A2 CO7151489 A2 CO 7151489A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
pyrimidinylcyclopentane
compound
amorphous form
Prior art date
Application number
CO14270817A
Other languages
English (en)
Inventor
Paroma Chakravarty
Sanjeev Kothari
Francis Gosselin
Scott J Savage
Jeffrey Stults
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48539412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7151489(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CO7151489A2 publication Critical patent/CO7151489A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Se describen monoclorhidrato de (S)-2-(4-clorofenil)-1-(4-((5R,7R)-7-hidroxi-5-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)piperazin-1-il)-3-(isopropilamino)propan-1-ona, formas, formulaciones, composiciones farmacéuticas, procesos de fabricación y métodos de uso de este.
CO14270817A 2012-05-17 2014-12-09 Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo CO7151489A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261648536P 2012-05-17 2012-05-17

Publications (1)

Publication Number Publication Date
CO7151489A2 true CO7151489A2 (es) 2014-12-29

Family

ID=48539412

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14270817A CO7151489A2 (es) 2012-05-17 2014-12-09 Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo

Country Status (31)

Country Link
US (2) US9290458B2 (es)
EP (2) EP3719014A1 (es)
JP (2) JP6283663B2 (es)
KR (4) KR20220143143A (es)
CN (1) CN104470912B (es)
AU (2) AU2013262548B2 (es)
BR (1) BR112014028593A2 (es)
CA (1) CA2873663C (es)
CL (1) CL2014003115A1 (es)
CO (1) CO7151489A2 (es)
CR (1) CR20140560A (es)
DK (1) DK2858989T3 (es)
ES (1) ES2799512T3 (es)
HK (1) HK1208462A1 (es)
HR (1) HRP20200992T1 (es)
HU (1) HUE051254T2 (es)
IL (2) IL235712B (es)
LT (1) LT2858989T (es)
MA (1) MA37650A1 (es)
MX (1) MX353041B (es)
MY (1) MY170086A (es)
NZ (1) NZ702513A (es)
PE (1) PE20150725A1 (es)
PH (1) PH12014502538A1 (es)
PL (1) PL2858989T3 (es)
PT (1) PT2858989T (es)
RS (1) RS60417B9 (es)
RU (1) RU2650511C2 (es)
SG (1) SG11201407618VA (es)
SI (1) SI2858989T1 (es)
WO (1) WO2013173811A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102067850B1 (ko) 2012-05-17 2020-01-17 어레이 바이오파마 인크. 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법
KR20220143143A (ko) 2012-05-17 2022-10-24 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
CA3207199A1 (en) * 2013-11-15 2015-05-21 F. Hoffmann-La Roche Ag Processes for the preparation of pyrimidinylcyclopentane compounds
EP2946774B1 (en) 2014-05-19 2020-04-22 Tillotts Pharma AG Modified release coated capsules
CN115350192A (zh) * 2016-08-10 2022-11-18 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
TW202120096A (zh) * 2019-08-12 2021-06-01 美商建南德克公司 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌
EP4351522A1 (en) * 2021-06-09 2024-04-17 Lonza Bend Inc. Mixed solvents for spray drying for preparation of amorphous solid dispersions
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
EP1158982A4 (en) 1999-03-03 2002-06-12 Merck & Co Inc Prenyl protein transferase inhibitors
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
RS61604A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2486181C2 (ru) 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
JP5346345B2 (ja) * 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
BR112012011328A2 (pt) 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
JP2013528787A (ja) * 2010-04-16 2013-07-11 ジェネンテック， インコーポレイテッド Ｐｉ３ｋ／ａｋｔキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのｆｏｘ０３ａ
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
KR102067850B1 (ko) 2012-05-17 2020-01-17 어레이 바이오파마 인크. 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법
CA2873661C (en) 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
KR20220143143A (ko) 2012-05-17 2022-10-24 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
US9309204B2 (en) 2012-05-17 2016-04-12 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
CA2901577A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JP2016520515A (ja) 2013-03-15 2016-07-14 シファ・バイオメディカル・コーポレイションＳｈｉｆａ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗ｐｃｓｋ９化合物および心血管疾患の治療および／または予防のための方法

Also Published As

Publication number Publication date
CA2873663A1 (en) 2013-11-21
CA2873663C (en) 2020-01-14
EP2858989B9 (en) 2021-04-14
US9290458B2 (en) 2016-03-22
AU2013262548A1 (en) 2015-01-15
JP6518352B2 (ja) 2019-05-22
IL235712B (en) 2020-01-30
LT2858989T (lt) 2020-08-10
JP6283663B2 (ja) 2018-02-21
PH12014502538B1 (en) 2015-01-21
EP2858989B1 (en) 2020-05-06
US20150274677A1 (en) 2015-10-01
ES2799512T3 (es) 2020-12-18
PE20150725A1 (es) 2015-05-17
RS60417B9 (sr) 2021-07-30
DK2858989T3 (da) 2020-06-02
MX353041B (es) 2017-12-18
MA37650A1 (fr) 2016-11-30
RU2650511C2 (ru) 2018-04-16
SG11201407618VA (en) 2015-01-29
AU2017279607C1 (en) 2019-05-16
KR20210095238A (ko) 2021-07-30
AU2017279607B2 (en) 2018-11-22
SI2858989T1 (sl) 2020-08-31
HRP20200992T1 (hr) 2020-10-16
IL272037B (en) 2020-10-29
PT2858989T (pt) 2020-06-25
MX2014013856A (es) 2015-02-18
PH12014502538A1 (en) 2015-01-21
HK1208462A1 (en) 2016-03-04
AU2013262548B2 (en) 2017-09-21
IL272037A (en) 2020-02-27
BR112014028593A2 (pt) 2017-12-19
IL235712A0 (en) 2015-02-01
MY170086A (en) 2019-07-04
CN104470912B (zh) 2017-11-14
WO2013173811A1 (en) 2013-11-21
KR20150020200A (ko) 2015-02-25
CR20140560A (es) 2015-01-12
RS60417B1 (sr) 2020-07-31
EP3719014A1 (en) 2020-10-07
AU2017279607A1 (en) 2018-01-18
NZ702513A (en) 2016-09-30
PL2858989T3 (pl) 2020-11-16
EP2858989A1 (en) 2015-04-15
JP2018062536A (ja) 2018-04-19
CL2014003115A1 (es) 2015-07-03
RU2014151016A (ru) 2016-07-10
US9505725B2 (en) 2016-11-29
JP2015517533A (ja) 2015-06-22
US20160152575A1 (en) 2016-06-02
KR20200074252A (ko) 2020-06-24
CN104470912A (zh) 2015-03-25
KR102125588B1 (ko) 2020-06-22
KR20220143143A (ko) 2022-10-24
HUE051254T2 (hu) 2021-03-01

Similar Documents

Publication Publication Date Title
CO7151489A2 (es) Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
CR20160102A (es) Formas de dosificación de liberación prolongada para un inhibidor de jak 1
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
EA201792116A1 (ru) Ингибитор янус-киназы
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
EP3797109A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
DK3699181T3 (da) Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
CL2014000468A1 (es) Compuestos derivados del acido 2-oxo-6-(fenil/heteroaril)l-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para el alivio de una infeccion bacteriana.
EA201490949A1 (ru) Ингибиторы киназ
EP3434676A4 (en) SUBSTITUTED PYRROLOPYRIMIDINE-CDK INHIBITORS, PHARMACEUTICAL COMPOSITION THEREFOR AND USE THEREOF
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
WO2014153495A9 (en) Novel stat3 inhibitors
MX354373B (es) Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
CL2015001730A1 (es) Compuestos triciclos inhibidores del canal cftr; composicion y combinacion farmaceutica; y uso en el tratamiento de la enfermedad renal poliquistica y diarrea.
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
PH12016500134B1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives